证券日报网2月4日讯 ，西山科技在接受调研者提问时表示，《手术与治疗辅助操作类医疗服务价格项 目立项指南（试行）》聚焦医疗技术前沿成果，围绕3D打印、示踪增强成像、能量器械、术中影像引 导、机械臂与远程手术等医疗科技创新成果进行统一价格立项，规范形成37项价格项目。这与公司"微 创手术工具整体方案提供者"的战略定位高度契合，公司产品线涵盖手术动力装置、内窥镜系统、能量 手术设备等，正是该指南中第12项、第15项、第20项、第23项重点支持的技术领域。具体来看，指南对 手术动力装置及能量手术器械（如超声刀、射频刀、等离子刀等）的收费政策进行了规范，有助于规范 相关耗材的使用及收费行为，为公司手术动力装置及能量手术设备相关耗材的使用创造更加积极的市场 环境。公司将继续深化耗材化战略，着力推动手术动力装置的持续普及应用及其刀头的耗材化。 （文章来源：证券日报） ...

Core Viewpoint - The report outlines the continuous supervision work conducted by Dongfang Securities for Chongqing Xishan Technology Co., Ltd. after its listing, confirming that the company has adhered to relevant regulations and has not encountered any legal violations during the supervision period [1][3]. Continuous Supervision Work - The sponsor has established and effectively implemented a continuous supervision work system, creating specific work plans for ongoing oversight [2]. - A sponsorship agreement was signed between the sponsor and the company, clarifying the rights and obligations of both parties during the supervision period [3]. - The sponsor has utilized various methods such as regular communication, site visits, and due diligence to monitor the company's business situation [3]. - During the supervision period, the company did not report any legal violations or breaches of commitments [3][4]. Company Governance and Internal Control - The sponsor has urged the company to establish and effectively implement corporate governance systems, including behavior norms for directors, supervisors, and senior management [4]. - The internal control systems, including financial management and auditing procedures, have been verified for effective execution [4]. - The company has been guided to strictly adhere to information disclosure regulations, ensuring that submitted documents do not contain false records or misleading statements [5]. Financial Performance - For the first half of 2025, the company reported operating income of 155.04 million yuan, a 2.40% increase compared to the same period last year [15]. - The net profit attributable to shareholders decreased by 41.62% to 34.38 million yuan, primarily due to reduced financial income and increased operational costs [16]. - The company’s total assets decreased by 3.88% to 1.85 billion yuan, attributed to share buybacks and cash dividends [16]. Research and Development - The company invested 24.74 million yuan in R&D during the first half of 2025, a 7.52% increase year-on-year, with R&D expenses accounting for 15.96% of operating income [17]. - The company holds 14 Class III medical device product registration certificates and has a total of 1,320 domestic patents, including 118 invention patents [17]. Industry Context - The medical device industry is a crucial part of the national economy and is subject to strict regulatory oversight, impacting the company's operations [14]. - The implementation of centralized procurement policies may affect the sales and pricing strategies of the company's products, necessitating adaptability to maintain competitiveness [13][14].

Group 1: Haier Biomedical - The overseas revenue distribution is 40% from Europe, 30% from Africa, 20% from Asia, and 10% from the Americas, with low-temperature storage market share below 10% [1] - Smart medication and blood technology each contribute 11% to revenue, while laboratory solutions account for 17%, with the former two being more profitable [1] - The company aims for a 15%-30% revenue growth through stock incentive plans, with significant growth in domestic large projects and a nearly 200% increase in medical projects [1] Group 2: Tuojing Life - The company focuses on invasive fungal disease detection, having completed restructuring and integration to enhance product development and clinical promotion [2] - The industry is significantly impacted by centralized procurement policies, with expectations for growth in self-immune testing, HPV screening, and thrombosis detection in the future [2] - The company has made a provision for asset impairment of approximately 13.44 million yuan, mainly due to bad debt losses and inventory adjustments [2] Group 3: Haitai New Light - Most products have been transferred to Thailand for mass production, with expectations to complete all product transfer approvals by Q3 [3] - Strong demand from overseas customers is anticipated, with continued growth in overseas shipments expected in the second half of the year [3] - The company has initiated cooperation with U.S. clients for the next-generation endoscope system, expanding from general surgery to head and neck surgery and orthopedics, which is expected to drive significant business growth [3]

Company Overview - Xishan Technology's closing price on August 14 was 70.46 yuan, down 4.03%, with a rolling PE ratio of 38.05 times and a total market capitalization of 3.206 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Xishan Technology at the 75th position in the industry ranking [1] - The company’s static PE ratio is 32.49 times, and its price-to-book ratio is 1.85 times [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xishan Technology in the medical device industry, noting its current stock price and market capitalization [1][2] - As of August 12, Xishan Technology's stock closed at 74.63 yuan, with a PE ratio of 40.30, marking a new low in 209 days, and a total market value of 3.396 billion yuan [1] - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, positioning Xishan Technology at the 75th rank within the industry [1][2] Group 2 - Xishan Technology's main business involves the research, manufacturing, sales, and service of surgical medical devices, including surgical power tools, endoscopic systems, and energy surgical equipment [1] - The latest financial results for Q1 2025 show that the company achieved a revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1]

Company Overview - Xishan Technology's closing price on August 8 was 72.56 yuan, up 1.94%, with a rolling PE ratio of 39.18, marking a new low in 207 days, and a total market capitalization of 3.301 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical instruments, including surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross profit margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, placing Xishan Technology at the 77th position in the industry ranking [1] - The company’s static PE ratio is 33.46, and its price-to-book ratio is 1.91 [2]

Group 1 - The core viewpoint of the news is that Xishan Technology's stock performance and financial metrics indicate a challenging position within the medical device industry, with a notably low PE ratio compared to industry averages [1][2] - As of August 5, Xishan Technology's closing price was 72.11 yuan, with a rolling PE ratio of 38.94, marking a 204-day low and a total market capitalization of 3.281 billion yuan [1] - The average PE ratio for the medical device industry is 54.24, with a median of 37.92, placing Xishan Technology at the 78th position in the industry ranking [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Xishan Technology achieved revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% [1] - The company's gross profit margin stands at 67.64%, indicating a relatively high profitability despite the decline in revenue and net profit [1] - Xishan Technology specializes in the research, manufacturing, sales, and service of surgical medical devices, with key products including surgical power tools, endoscopic systems, and energy surgical equipment [1]

Core Viewpoint - The company intends to temporarily use part of its idle raised funds, not exceeding RMB 150 million, to supplement its working capital while ensuring the normal progress of its fundraising projects [4][6]. Fundraising Basic Situation - The company successfully issued 21,780,000 shares at a price of RMB 35.76 per share, raising a total of RMB 778.85 million, with a net amount of RMB 693.52 million after deducting underwriting fees [1]. Fundraising Management - The company has established a special account for managing the raised funds and signed a tripartite supervision agreement with the sponsor and the bank where the funds are deposited [2]. Investment Project Situation - The company has adjusted its fundraising investment plan, with a total planned investment of RMB 862.37 million, of which RMB 693.52 million is allocated to various projects, including the construction of an endoscope production base and a research and experimental center [3]. Plan for Using Idle Funds - The company plans to use idle funds to meet working capital needs, improve fund utilization efficiency, and enhance profitability, ensuring that the funds will only be used for business expansion and daily operations related to its main business [4][5]. Approval Process - The company held board and supervisory meetings to approve the use of idle funds, confirming that the process complies with relevant laws and regulations, and does not affect the normal progress of fundraising projects [6]. Special Opinions - The supervisory board agrees that the use of idle funds will not change the intended use of the raised funds and will not harm the interests of the company and its shareholders [6]. Sponsor's Verification Opinion - The sponsor has verified that the approval process for using idle funds has been properly followed and that the funds will be used in accordance with regulations, ensuring no impact on the fundraising investment plan [6].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xishan Technology in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, Xishan Technology's stock closed at 68.09 yuan, with a rolling PE ratio of 36.77, marking a new low in 61 days, and a total market value of 3.098 billion yuan [1] - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, positioning Xishan Technology at the 74th rank within the industry [1][2] Group 2 - The company specializes in the research, manufacturing, sales, and service of surgical medical devices, with key products including surgical power tools, endoscopic systems, and energy surgical equipment [1] - In the latest quarterly report for Q1 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66%, with a gross margin of 67.64% [1]

Core Viewpoint - Xishan Technology (688576.SH) is facing significant challenges with declining revenue and profits, prompting investor concerns and discussions about the company's future strategies and stock buyback practices [1][2][3] Group 1: Company Overview - Xishan Technology, headquartered in Chongqing, specializes in surgical power devices, endoscopic systems, and energy surgical equipment, serving various clinical departments [1] - The company went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 6, 2023, with a strategic placement of shares [1] Group 2: Financial Performance - In 2024, Xishan Technology reported a revenue of 336 million yuan, a year-on-year decrease of 6.74%, and a net profit of 71.71 million yuan, down 22.45% [1] - For Q1 2025, the company generated revenue of 65.88 million yuan, a decline of 11.2% year-on-year, and a net profit of 8.99 million yuan, down 55.02% [2] Group 3: Investor Concerns - Investors have expressed concerns regarding the company's continuous revenue decline and significant profit drops since its IPO, questioning the effectiveness of the company's strategies to reverse this trend [2][3] - Xishan Technology has conducted multiple share buybacks, totaling approximately 490 million yuan, which has not positively impacted the stock price, leading to further investor dissatisfaction [3] Group 4: Stock Performance - As of June 9, 2025, Xishan Technology's stock price was 64.55 yuan per share, representing a decline of about 52.4% from its initial offering price of 135.80 yuan [3]